| P2093 | author name string | Jing Fang | |
| | Pravin R Jadhav | |
| P2860 | cites work | Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS) | Q22242256 |
| | Perspectives on the basic reproductive ratio | Q24669998 |
| | Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells | Q28369295 |
| | Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. | Q33697044 |
| | Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy | Q33938112 |
| | The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects | Q34486811 |
| | Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects | Q34560437 |
| | A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects | Q34589338 |
| | Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics | Q35817013 |
| | Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers | Q36558240 |
| | Quantitative disease, drug, and trial models | Q37292641 |
| | Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs | Q37345610 |
| | New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. | Q37579219 |
| | Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action | Q37650120 |
| | The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property? | Q39907784 |
| | Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling | Q40246920 |
| | Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: a randomized trial of double versus triple therapy. Swiss HIV Cohort Study | Q43718392 |
| | Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance | Q43719445 |
| | Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals | Q44605402 |
| | Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay | Q44668486 |
| | A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc | Q46830659 |
| | Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006. | Q47569147 |
| | Quantification of in vivo replicative capacity of HIV-1 in different compartments of infected cells | Q56930579 |
| | A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc | Q83202545 |
| P433 | issue | 4 | |
| P921 | main subject | anti-retroviral agent | Q50430310 |
| P304 | page(s) | 357-368 | |
| P577 | publication date | 2012-06-27 | |
| P1433 | published in | Journal of Pharmacokinetics and Pharmacodynamics | Q15766045 |
| P1476 | title | From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework | |
| P478 | volume | 39 | |